Tanya Zapolskaya1, Sarah Perreault2, Dayna McManus1, Jeffrey E Topal3. 1. Department of Pharmacy, Yale-New Haven Hospital, 20 York Street, New Haven, CT, 06510, USA. 2. Department of Pharmacy, Yale-New Haven Hospital, 20 York Street, New Haven, CT, 06510, USA. Sarah.Perreault@ynhh.org. 3. Department of Internal Medicine, Infectious Disease Section, Yale-New Haven Hospital, 20 York Street, New Haven, CT, 06510, USA.
Abstract
PURPOSE: Prolonged and profound neutropenia is common among hematology and hematopoietic stem cell transplant (HSCT) patients as a result of chemotherapy. The National Comprehensive Cancer Network (NCCN) and Infectious Diseases Society of America (IDSA) currently recommend antibacterial prophylaxis in patients who are deemed at intermediate or high risk for infection. Specifically, fluoroquinolone prophylaxis should be considered for high-risk neutropenic patients. However, with prolonged and frequent exposure to fluoroquinolones, these high-risk patients may develop resistance to these agents. Patients may also have allergies or other contraindications which prohibit the use of fluoroquinolones for antibacterial prophylaxis. Unfortunately, there is no standard recommendation for alternative antimicrobial therapy in this patient population, as well as there is a lack of data to support the use of potential alternative agents. METHODS: Currently, Yale-New Haven Hospital utilizes fosfomycin for antibacterial prophylaxis in patients who are not eligible for fluoroquinolone therapy. The primary objective of this study was to assess the incidence of breakthrough infections in this population receiving fosfomycin. Secondary objectives included organisms identified, types of breakthrough infections, resistance patterns, and time from initiation to onset of fever. RESULTS: Of the 42 patients who received fosfomycin, 25 patients with 42 admissions met inclusion criteria. A total of 8 (19%) breakthrough infections occurred during the 42 admissions. Organisms included Klebsiella spp. (5), Streptococcus mitis/viridans (2), Pseudomonas aeruginosa (1), and coagulase-negative staphylococcus (1). Infections included the following: bacteremia (7), cellulitis (1), and urine (1). CONCLUSION: Given the low rate of breakthrough infections, fosfomycin may be a potential alternative option for antibacterial prophylaxis.
PURPOSE: Prolonged and profound neutropenia is common among hematology and hematopoietic stem cell transplant (HSCT) patients as a result of chemotherapy. The National Comprehensive Cancer Network (NCCN) and Infectious Diseases Society of America (IDSA) currently recommend antibacterial prophylaxis in patients who are deemed at intermediate or high risk for infection. Specifically, fluoroquinolone prophylaxis should be considered for high-risk neutropenicpatients. However, with prolonged and frequent exposure to fluoroquinolones, these high-risk patients may develop resistance to these agents. Patients may also have allergies or other contraindications which prohibit the use of fluoroquinolones for antibacterial prophylaxis. Unfortunately, there is no standard recommendation for alternative antimicrobial therapy in this patient population, as well as there is a lack of data to support the use of potential alternative agents. METHODS: Currently, Yale-New Haven Hospital utilizes fosfomycin for antibacterial prophylaxis in patients who are not eligible for fluoroquinolone therapy. The primary objective of this study was to assess the incidence of breakthrough infections in this population receiving fosfomycin. Secondary objectives included organisms identified, types of breakthrough infections, resistance patterns, and time from initiation to onset of fever. RESULTS: Of the 42 patients who received fosfomycin, 25 patients with 42 admissions met inclusion criteria. A total of 8 (19%) breakthrough infections occurred during the 42 admissions. Organisms included Klebsiella spp. (5), Streptococcus mitis/viridans (2), Pseudomonas aeruginosa (1), and coagulase-negative staphylococcus (1). Infections included the following: bacteremia (7), cellulitis (1), and urine (1). CONCLUSION: Given the low rate of breakthrough infections, fosfomycin may be a potential alternative option for antibacterial prophylaxis.
Authors: Lindsey Robert Baden; Sankar Swaminathan; Michael Angarone; Gayle Blouin; Bernard C Camins; Corey Casper; Brenda Cooper; Erik R Dubberke; Ashley Morris Engemann; Alison G Freifeld; John N Greene; James I Ito; Daniel R Kaul; Mark E Lustberg; Jose G Montoya; Ken Rolston; Gowri Satyanarayana; Brahm Segal; Susan K Seo; Shmuel Shoham; Randy Taplitz; Jeffrey Topal; John W Wilson; Karin G Hoffmann; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2016-07 Impact factor: 11.908
Authors: Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Michael Cullen; Neil Steven; Lucinda Billingham; Claire Gaunt; Mark Hastings; Peter Simmonds; Nicholas Stuart; Daniel Rea; Mark Bower; Indrajit Fernando; Robert Huddart; Simon Gollins; Andrew Stanley Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245
Authors: Giampaolo Bucaneve; Alessandra Micozzi; Francesco Menichetti; Pietro Martino; M Stella Dionisi; Giovanni Martinelli; Bernardino Allione; Domenico D'Antonio; Maurizio Buelli; A Maria Nosari; Daniela Cilloni; Eliana Zuffa; Renato Cantaffa; Giorgina Specchia; Sergio Amadori; Francesco Fabbiano; Giorgio Lambertenghi Deliliers; Francesco Lauria; Robin Foà; Albano Del Favero Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079